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Background: Epidermal growth factor receptor (EGFR) activating mutations are
usually associated with DNA damage repair (DDR) deﬁciency. However, the pre-
cise mechanism has remained elusive. In this study, we aimed to investigate
whether EGFR exon 19 deletion mutation downstream signals contributed to
DDR deﬁciency by downregulation of excision repair cross-complementation
group-1 (ERCC1), a key factor in DDR, expression and function.
Methods: We ﬁrst measured cell survival, DNA damage (γ-H2AX foci forma-
tion) and damage repair (ERCC1 and RAD51 foci formation) ability in response
to DNA cross-linking drug in EGFR exon 19 deletion and EGFR wild-type cells
separately. We then investigated the involvement of EGFR downstream signals in
regulating ERCC1 expression and function in EGFR exon 19 deletion cells as
compared with EGFR wild-type ones.
Results: We observed increased γ-H2AX, but impaired ERCC1 and RAD51
nuclear foci formation in EGFR exon 19 deletion cells as compared with EGFR
wild-type ones treated with DNA cross-linker. In addition, we identiﬁed that
inhibition of EGFR exon 19 deletion signals increased ERCC1 expression,
whereas blocked wild-type EGFR signals decreased ERCC1 expression, on both
mRNA and protein levels. Furthermore, EGFR exon 19 deletion downstream sig-
nals not only inhibited ERCC1 expression but also inﬂuenced ERCC1 foci forma-
tion in response to DNA cross-linker.
Conclusion: Our ﬁndings indicated that the aberrant EGFR exon 19 deletion
signals were not only associated with decreased expression of ERCC1 but were
also involved in impaired ERCC1 recruitment in response to DNA cross-link
damage, thereby providing us with more evidence for exploring the mechanism
of DDR deﬁciency in EGFR mutant NSCLC.
Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide and approximately 85% of lung cancers are
non-small cell lung cancer (NSCLC).1 Epidermal growth
factor receptors (EGFR) are highly expressed in many
malignant neoplasms. A total of 40%–60% NSCLC tumors
show EGFR overexpression.2,3 EGFR overexpression is usu-
ally associated with tumor invasion, metastasis and
increased proliferation. EGFR has also been reported to
promote DNA damage repair (DDR).4 Interestingly,
NSCLC harboring EGFR activating mutations have previ-
ously been reported to be related to DDR deﬁciency which
usually demonstrated as sensitivity to chemotherapy and
radiotherapy, but the mechanism has remained elusive.5,6
Recently, a link between EGFR and excision repair
cross-complementation group-1 (ERCC1) has been
reported. ERCC1 is a crucial factor involved in a number
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of DNA repair pathways in mammalian cells.7 It is essen-
tial for nucleotide excision repair (NER) and also has
important roles in interstrand cross-link (ICL) and double-
strand break (DSB) repair.8 Preliminary explorations have
been made to investigate the relationship between EGFR
and ERCC1. First, Liccardi et al. reported that wild-type
EGFR could translocate to the nucleus and bind with
ERCC1 following DNA DSB induced directly by irradia-
tion. This EGFR-ERCC1 interaction was observed to be
involved in DDR.9 Second, even without any DNA damage,
Andrieux et al. determined that stimulation of wild-type
EGFR by its natural ligand epidermal growth factor (EGF)
could increase ERCC1 expression through ERK pathway in
hepatocyte and hepatocellular carcinoma cell lines.10
It is worth noting that NSCLC harboring EGFR activating
mutations have been reported to demonstrate decreased
levels of ERCC1 expression.11,12 Most of these activating
mutations occurred in EGFR gene exons 19 to 21 which
encode the tyrosine kinase domain. Studies have revealed
that mutations of kinase domains may facilitate EGFR
dimerization, which in turn could promote kinase activity
which gives rise to constitutive aberrant survival signals.13
Tyrosine kinase inhibitor (TKI) could inhibit this kinase
activity effectively, block its downstream survival signals,
and lead to cancer cell death.14 Thus, these survival signals
raised by mutant EGFR have been reported to be onco-
genic and tumor driver; however, the exact mechanism is
still obscure. Considering that wild-type EGFR downstream
pathways could upregulate ERCC1 expression, we question
whether the aberrant signals raised by mutant EGFR con-
tribute to downregulation of ERCC1 in mutant EGFR
NSCLC cells. If this is the case, we suggest that the
decreased ERCC1 expression and impaired ERCC1 function
induced by mutant EGFR signals may relate to tumorigene-
sis, as well as chemosensitivity, in NSCLC with EGFR acti-
vating mutations.
Evidence has revealed that the clinical outcomes of dif-
ferent EGFR mutation genotypes were varied. Exon 19 dele-
tion is one of the most common activating EGFR
mutations in NSCLC. In this study, we sought to explore
the regulation of EGFR exon 19 deletion constitutive acti-




The human bronchial epithelial cell lines, BEAS-2B and
SAEC T1, were provided by Hanna K Lindberg (Finnish
Institute of Occupational Health, Finland). NSCLC harbor-
ing EGFR exon 19 deletion cell line PC9 was purchased
from Sigma-Aldrich, Germany (90071810); and EGFR
exon21 L855R mutation cell line HCC827 from the ATCC,
USA (CRL-2868). EGFR wild-type NSCLC A549 and NCI-
H2126 cell lines were provided by Dr Emmy Verschuren
(Institute for Molecular Medicine Finland, Finland).
EGFR-null NIH-3T3 mouse embryonic ﬁbroblasts (MEFs)
were provided by the Oral cancer research group
(University of Helsinki, Finland).
Culture conditions: PC9 cells were maintained in RPMI-
1640; A549, HCC827, and NIH-3T3 cells were grown in
Dulbecco’s Modiﬁed Eagle Medium (DMEM); and NCI-
H2126 in DMEM/F12. Culture media supplements were
10% bovine growth serum (FBS) (HyClone SH30071.03),
10 mM HEPES (Gibco 15630–056), 2 mM L-glutamine
(Gibco 35050–038) and 1 mM sodium pyruvate (Gibco
11360–039). BEAS-2B cells were cultured in LHC-9
medium (Thermo Fisher 12680013). All the above cells
were grown at 37C in a humidiﬁed atmosphere with 5%
CO2, and were in the logarithmic growth phase at the initi-
ation of the experiments.
Generation of MEFs expressing wild-type
and exon 19 deletion human EGFR
NIH-3T3 cells were seeded in a six well plate at 10%–25%
conﬂuency. They were then transfected with the retroviral
pBABE-puromycin expression vector encoding human wild-
type EGFR or and mutant EGFR (exon 19 delL747-E749 or
exon21 L858R mutation) by retrovirus. Polybrene was added
to each well at 8 μg/mL ﬁnal concentration. The pBABE-
wild type EGFR plasmid, pBABE-EGFR exon19 deletion
plasmid, pBABE-EGFR exon21 L858R plasmid and pBABE-
puro plasmid were obtained from the Addgene plasmid
repository15,16 (11011,11015,11012,1764). To select for stably
transfected clones, puromycin-containing media (ﬁnal con-
centration 1 μg/mL) was added to the cells approximately
18–20 hours after infection.
Treatments
Exponentially growing lung cancer cells, human bronchial
epithelial cells and transfected NIH-3T3 cells were seeded
in six-well plates, allowed to grow for 24 hours, and then
collected for western blot analysis to measure protein
expression. For inhibition of EGFR signals, cells were ﬁrst
cultured in serum-supplemented media for 24 hours which
was then replaced by media containing 0.1% FBS with or
without 1 μM geﬁtinib, an EGFR-TKI, (Iressa 250mg
AstraZeneca) for further incubation.
To analyze ERCC1 dynamics in response to cisplatin,
we placed exponentially growing NSCLC cells in a 96 well
plate and treated the cells with 5 μM cisplatin (Sigma
P4394) for 6, 12, 24, 48 hours and ﬁxed for further analy-
sis of the DNA damage and repair. In order to analyze
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the role of EGFR downstream pathways on ERCC1
recruitment in response to DNA damage, we ﬁrst cul-
tured lung cancer cells in low-serum medium (0.1% FBS)
containing 1 μM geﬁtinib for six hours, then treated the
cells with 5 μM cisplatin in full medium for 6, 12, 24 and
48 hours.
Western blot analysis
Cells were washed with ice-cold phosphate-buffered saline
(PBS) and scraped immediately after adding 100 μL of cold
RIPA buffer (Thermo 89 900) supplemented with protease
inhibitor cocktail Set III, Animal Free (Calbiochem
535 140). Protein concentrations were measured using
PieceTM BCA Protein Assay Kit (Thermo 23 227). For
each sample, the same amount of total protein was added
to a well of a 12% acrylamide gel and resolved by SDS-
PAGE. 1:150 dilution of antibody against human ERCC1
(Santa Cruz sc-17 809), 1:1000 dilution of p44/42 MAPK
(CST 4695), 1:2000 dilution of Phospho-p44/42 MAPK
(CST 4370) and 1:5000 of anti-β-actin (Sigma A5441) were
used as primary antibodies. 1:5000 dilutions of HRP Don-
key anti-mouse or HRP Donkey anti-rabbit IgG secondary
antibodies (ThermoFisher A16017, A16035) were used.
Proteins were detected with Clarity Western ECL Substrate
(Bio-Rad 170–5060) followed by Odyssey Fctoradiography
(Li-Cor 0720). The western blot images were analyzed
using ImageJ software version 2.0.
Immunoﬂuorescence microscopy
Exponentially growing cells were ﬁxed at different time
points after treatment with 5 μM cisplatin (Sigma P4394)
or 5 Gy gamma irradiation as follows. Cells were ﬁxed
with 2% PFA/PBS++ (PBS++: PBS with 1 mM CaCl2 and
0.5 mM MgCl2) for 10 minutes at 4C, then perme-
abilized with 0.2% Triton X-100 in PBS++ for 20 minutes.
After blocking with staining buffer (0.5% BSA, 0.15%gly-
cin, 0.1% Triton X-100 in PBS++), they were exposed to
primary antibodies against γ-H2AX (Abcam ab22551;
1:1000 in staining buffer), ERCC1 (D-10, Santa Cruz sc-
17 809; diluted 1:50 in 10% donkey serum in PBS) or
RAD51 (Abcam ab22551, 1:500 in staining buffer) over-
night at 4C, subsequently incubated with secondary anti-
bodies for one hour at room temperature (Alexa Fluor
488 donkey anti-mouse, 1:500 in staining buffer, Invi-
trogen A-21202 and Alexa Fluor 647 donkey anti-rabbit,
1:500, Invitrogen A-31573). Nuclear foci were scored
using the Thermo Scientiﬁc CellInsight high content
imaging system.
Cell survival assays
Cell viability was measured by Trypan blue exclusion
staining and tested by Countess™ automated cell counter
(Invitrogen C10227).
Statistical analysis
Statistical comparisons were calculated using Student’s t-
test in SAS version 9. A P-value of <0.05 was considered as
statistically signiﬁcant.
Results
Association of EGFR exon 19 deletion with
DNA damage repair deﬁciency
DDR deﬁciency is usually related to DNA damage drug sen-
sitivity. In order to determine that DDR deﬁciency was asso-
ciated with EGFR exon 19 deletion, we ﬁrst studied cell
survival in response to cisplatin (DNA cross-linking drug)
in both NSCLC cell lines and NIH3T3 MEFs expressing
either wild-type EGFR or EGFR harboring exon 19 deletion
mutation. As shown in Figure 1a,b, NIH3T3 MEFs with
exogenous EGFR exon 19 deletion were associated with
lower cell-survival fraction as compared with those of wild-
type EGFR. In lung cancer cell lines, we also observed that
EGFR exon 19 deletion NSCLC cell line showed a lower sur-
vival rate than EGFR wild-type ones after 5 μM cisplatin
treatment (Fig 1c). In addition, γ-H2AX, a marker for DNA
double-stranded breaks, was also observed. We found obvi-
ously increased γ-H2AX foci formation in EGFR-mutant
PC9 cells as compared with wild-type NSCLC cell lines in
response to cisplatin (Fig 1d). These results together indi-
cated that cells with EGFR exon 19 deletion were associated
with deﬁciency of DNA damage repair.
ERCC1 formation detected in EGFR exon
19 deletion cells
ERCC1 is an essential protein in the NER pathway and Fan-
coni anemia pathway which is responsible for ICL unhooking
and DNA DSB formation. To investigate the difference of
ERCC1 protein function in EGFR wild-type and exon 19 dele-
tion NSCLC cells, we detected the formation of nuclear
ERCC1 foci in response to DNA cross-linking drug cisplatin
by immunoﬂuorescence. As shown in Figure 2a,b, we found
a substantially increased number of nuclear ERCC1 foci
24 hours after cisplatin administration in wild-type EGFR
NSCLC cell lines, as compared with PC9 cells. In addition, our
results showed that the ability of EGFR-mutant and wild-type
NSCLC cell lines to form ERCC1 foci in response to cisplatin
correlated with their survival after cisplatin treatment (Fig 2c).
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Next, we determined whether the impaired Fanconi ane-
mia pathway disrupted by ERCC1 affected the downstream
homologous recombination (HR) repair pathway in EGFR
exon 19 deletion NSCLC cells. RAD51, an important factor
in HR pathway, was detected as a marker here. We observed
that EGFR mutant PC9 cells exhibited defective formation
of RAD51 foci in response to cisplatin as compared with
EGFR wild-type NSCLC cell lines (Fig 2d,e). However, we
found the number of RAD51 foci increased signiﬁcantly in
both A549 and PC9 cells when the DSB caused directly by
gamma irradiation (with no ICL unhooking process)
(Fig 2e). Thus, it was possible to conclude that EGFR exon
19 deletion was associated with ERCC1 formation defects,
which led to impaired response to DNA cross-linking dam-
age and sensitivity to cisplatin treatment.
Aberrant regulation of ERCC1 by EGFR
exon 19 deletion signals
In order to determine the relationship between EGFR
exon 19 deletion and DNA damage repair gene ERCC1,
we ﬁrst screened ERCC1 expression in a panel of lung
cell lines by western blot assay. We found both protein
and mRNA expression level of ERCC1 in EGFR exon
19 deletion lung cancer cell line (PC9) were lower than
EGFR wild-type cancer cell lines and noncancerous
human bronchial epithelial cell lines (Fig 3a,b). Then, we
measured ERCC1 levels in NIH3T3 cells that stably
expressed human EGFR wild-type and exon 19 deletion
vector. In these cell lines, we found that the protein
expression ratio of ERCC1/β-actin was lower in NIH3T3
cells harboring EGFR exon 19 deletion than cells with
wild-type EGFR (Fig 3c). These results demonstrated
that EGFR exon 19 deletion was linked with lower
expression of ERCC1.
Based on the above results, we further investigated
our prediction that EGFR exon 19 deletion signals
might take part in downregulation of ERCC1. To test
this possibility, we ﬁrst used EGFR-TKI (geﬁtinib) to
inhibit both mutant and wild-type EGFR downstream
signals, and then analyzed ERCC1 protein and mRNA
expression levels in both NSCLC cell lines and in
NIH3T3 MEFs. Total ERK and phosphorylated ERK
Figure 1 DNA damage repair
(DDR) deﬁciency and DNA cross-
linker sensitivity of EGFR exon
19 deletion cells. (a) Western
blot showed protein expression
of human EGFR in NIH3T3 MEFs
transfected with EGFR wild-type
or exon 19 deletion vectors. (b)
Relative cell survival rate of wild-
type and del19 mutation EGFR
transfected NIH3T3 MEFs cells
after 5 μmol/L cisplatin treatment
at different time points. (c) Rela-
tive cell survival rate of NSCLC
cell lines after 5 μmol/L cisplatin
treatment at different time
points. (d) Percentage of γH2AX
foci positive cells induced by
5 μmol/L cisplatin at different
time points. All data represent
mean  SD based on two to
three biology repeats. Student’s
t-test was used for statistical
analysis between EGFR exon
19 deletion and each EGFR wild-
type groups. * P < 0.05.
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protein were stained in the meantime to identify the
inhibition effect of EGFR downstream signals. After
EGFR inhibition, we found that NIH3T3 MEFs trans-
fected with EGFR exon 19 deletion constructs demon-
strated a higher expression of ERCC1 as compared with
their corresponding controls; whereas NIH3T3 with
wild-type EGFR showed lower ERCC1 expression after
geﬁtinib treatment (Fig 3c,e). In lung cancer cell lines,
PC9 cells showed increased ERCC1 expression after
geﬁtinib treatment. However, A549, H2126 and BEAS-
2B with wild-type EGFR all showed decreased ERCC1
expression levels after EGFR signal inhibition (Fig 3d,
f ). Different from wild-type EGFR regulation on
ERCC1 expression, these results indicated EGFR exon
19 deletion downstream signals took part in down-
regulation of ERCC1 expression on both mRNA and
protein levels.
EGFR exon 19 deletion signals involved in
ERCC1 blocking in response to cross-
linking drug
To determine whether the signal transduction pathways
downstream of mutant EGFR were involved in impaired
ERCC1 recruitment in response to cisplatin, we ﬁrst
treated EGFR exon 19 deletion PC9 cells, and together
with EGFR wild-type A549 as control, with geﬁtinib for
six hours; then added cisplatin and observed the ERCC1
response. We found an increased percentage of ERCC1
foci after EGFR downstream signals blocked by geﬁtinib
in response to cisplatin in PC9 cells; while there was
decreased ERCC1 foci formation when EGFR signals
were inhibited in A549 cells (Fig 4a). That is to say,
EGFR exon 19 deletion downstream signals not only
inhibited ERCC1 expression but also inﬂuenced ERCC1
Figure 2 ERCC1 formation defects in EGFR exon 19 deletion cells in response to cross-linking drug cisplatin in NSCLC cell lines. (a) Percentage of
ERCC1 foci positive cells induced by 5μmol/L cisplatin at different time points. (b) Representative immunoﬂuorescence microscopy images of nuclei
with ERCC1 foci induced 24 hours after treatment with 5 μmol/L cisplatin. (c) Correlation of cisplatin survival rate with fraction of cells with induced
ERCC1 foci. (d) Percentage of RAD51 foci positive cells induced 24 hours after 5 μmol/L cisplatin. (e) Representative immunoﬂuorescence images of
nuclei with Rad51 foci induced 24 hours after treatment with 5 μmol/L cisplatin or 5Gy gamma irradiation (IR). All data represent mean  SD based
on two to three biology repeats. Student’s t-test was used for statistical analysis between different groups. * P < 0.05.
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foci formation which reﬂected DNA damage repair
capacity.
In addition, we investigated whether exon 19 deletion
EGFR signals impaired ERCC1 function, thereby blocking
the downstream RAD51 foci rescue in response to cis-
platin. However, we did not observe any stimulation of
cisplatin-induced RAD51 foci formation after inhibition of
mutant EGFR pathway by geﬁtinib, nor did we ﬁnd any
suppression of RAD51 foci formation in EGFR wild-type
A549 cells upon inhibition of EGFR signals (Fig 4b). These
results indicated that EGFR affects ERCC1 expression and
function in a kinase dependent way; however, EGFR
signals were not involved in the regulation of RAD51
recruitment in response to DNA damage. Thus, it was pos-
sible to conclude that EGFR exon 19 deletion signals might
impair DDR on ERCC1 level, but not by disrupting
RAD51 function, and other underlying mechanisms still
need to be investigated.
Discussion
NSCLC patients harboring EGFR activating mutations
have been reported to be related to an increased response
Figure 3 Regulation of ERCC1 by EGFR exon 19 deletion signals. (a) Western blot showing ERCC1 expression levels in NSCLC and human bronchial
epithelial cell lines. (b) RT-PCR showing mRNA level of ERCC1 expression in NSCLC and human bronchial epithelial cell lines. (c) Western blot analysis
of ERCC1, phosphorylated ERK, total ERK protein expression in NIH3T3 MEFs transfected with different EGFR vectors, before and six hours after
treated with geﬁtinib. (d) Western blot analysis of ERCC1, phosphorylated ERK, and total ERK protein expression in NSCLC cancer cell lines, before
and six hours after treated with geﬁtinib. ERCC1 values were expressed as ratio to those of corresponding controls. (e) RT-PCR analysis of ERCC1
mRNA expression of NIH3T3 MEFs transfected with wild-type and 19 deletion EGFR vectors, before and six hours after treated with geﬁtinib. (f) RT-
PCR analysis of ERCC1 mRNA expression of NSCLC cell lines, before and six hours after treated with geﬁtinib. All data represent mean  SD based
on two to three biology repeats. Student’s t-test was used for statistical analysis between different groups. * P < 0.05.
6 Thoracic Cancer (2020) © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
EGFR mutation regulated DDR through ERCC1 in NSCLC L. Zhang et al.
to platinum-based chemotherapies as compared with
EGFR wild-type patients.17 Some studies have indicated
that EGFR activating mutations may correlate with DNA
damage repair deﬁciency.18 Different from wild-type EGFR
regulation on ERCC1 expression, in our study, we found
EGFR exon 19 deletion signals could aberrantly down-
regulate ERCC1 expression. This result provided us with
evidence to explain and further explore the mechanism of
DDR deﬁciency in EGFR mutant NSCLC. In addition,
EGFR exon19 deletion and exon21 L858R mutations are
two common EGFR activating mutations. Interestingly,
even though we found the regulation of EGFR exon
19 deletion on ERCC1, we did not ﬁnd any regulatory rela-
tionship between EGFR L858R mutation signals and
ERCC1 expression as demonstrated in our Supplementary
data (Fig S1a,b). More and more clinical data revealed
EGFR 19 deletion and 21 L858R mutation demonstrated
different responses to treatments and clinical outcomes. It
has been shown that patients harboring EGFR exon
19 deletion mutation respond better not only to EGFR-
TKIs but also to platinum-based chemotherapy than
patients with EGFR L858R mutation, but the underlying
mechanism remains elusive.19,20 With regard to our results,
we suspected that downregulation of ERCC1 by EGFR
exon 19 deletion signals impaired DNA damage repair
ability could be the reason to explain that NSCLC with
EGFR exon 19 deletion showed better response to plati-
num as compared with EGFR L858R mutation.
In our study, we found EGFR exon 19 deletion down-
stream signals not only inhibited ERCC1 expression but
also inﬂuenced ERCC1 function in response to DNA dam-
age. In mammalian cells, ERCC1 protein acts as an endo-
nuclease in DNA damage repair process. It usually forms a
highly conserved unhooking endonuclease complex with
XPF that stabilizes both proteins for their roles in ICL
repair and HR.21 In addition to ERCC1, our study also
observed that XPF mRNA expression was decreased in
EGFR exon 19 deletion NSCLC cells as compared with
EGFR wild-type ones (Fig S1c). Thus, we wondered
whether the mutant EGFR signals inﬂuenced one
unhooking endonuclease and other endonucleases were
blocked as a result, or the mutant EGFR signals affected
several ICL unhooking endonucleases together. A previous
study revealed another endonuclease, FAN1, recruitment
defect in mutant EGFR NSCLC cells in response to DNA
ICL.22 FAN1 was a structure-selective nuclease recruited to
sites of cross-link damage through binding the
ubiquitinated FANCI-FANCD2 complex.23 Notably,
ERCC1 action on unhooking DNA ICL also depended on
ubiquitination of FANCD2.24 However, it was reported
that, in response to DNA cross-linker, ubiquitinated
FANCD2 level and FANCD2 foci formation were demon-
strated to be similar in EGFR mutant cells as compared
with EGFR wild-type cells.22 With these data together, we
indicated EGFR mutation affected DDR at the level of
decreased DNA endonuclease expression and impaired
endonuclease recruitment, which further reduced ICL inci-
sion and unhooking process.
Disrupted ICL unhooking pathway could affect aspects
of downstream HR process in mutant EGFR NSCLC cells,
Figure 4 EGFR exon 19 deletion signals were involved in ERCC1 blocking in response to cross-linking drug. (a) Average percentage of ERCC1 foci
positive cells in geﬁtinib-treated NSCLC cells, 24 hours after administration of 5 μmol/L cisplatin. (b) Average percentage of RAD51 foci positive cells
in geﬁtinib-treated NSCLC cells, 24 hours after administration of 5 μmol/L cisplatin. Cells were exposed to geﬁtinib six hours before adding cisplatin.
All data represent mean  SD based on two to three biology repeats. Student’s t-test was used for statistical analysis between different groups.
* P < 0.05.
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which was detected in our study by impaired RAD51 foci
formation in response to cisplatin. However, in our results,
RAD51 foci accumulation did not decrease when DNA
DSB was induced directly by gamma irradiation in EGFR
mutant PC9 cells. These results, on the other hand,
suggested that the DDR deﬁciency induced by EGFR exon
19 deletion was interrupted on the level of ICL unhooking
and DNA incision. In addition, even though we found
EGFR exon 19 deletion signals inﬂuenced ERCC1 foci for-
mation in response to cisplatin, no stimulation of cisplatin-
induced RAD51 foci formation has been found after inhi-
bition of the mutant EGFR pathway. A previous study rev-
ealed that transfection wild-type EGFR into PC9 cells
could rescue RAD51 foci formation, while overexpression
of mutant EGFR into A549 wild-type cells reduced RAD51
foci recruitment in response to cisplatin.22 Thus, it is possi-
ble to deduce that mutant EGFR not only disrupts ERCC1
recruitment but also some other damage repair factors in a
kinase independent matter, so that one-ended DSB sub-
strate at the stalled fork cannot be produced properly
which inﬂuence recruitment of RAD51 foci.
Even though we detected some regulation mechanism
of EGFR exon 19 deletion signals on ERCC1 function,
the exact entire regulation mechanism of EGFR exon
19 deletion on DDR deﬁciency is presently still far
beyond our knowledge. In response to gamma irradia-
tion, it was possible for wild-type EGFR to translocate to
the nucleus and then interact with ERCC1 to modulate
DNA DSB9; while mutant EGFR, including exon 19 dele-
tion and exon 21 L858R mutation, was unable to do so.6
In response to cisplatin, wild-type EGFR could also
translocate to the nucleus and bind to DNA protein
kinase complex (DNA-PK), which is an important pro-
tein in the NHEJ pathway. However, cells expressing
EGFR L858R mutation could not translocate to the
nucleus.25 Our study revealed a kinase dependent regula-
tion of EGFR exon19 deletion signals on ERCC1 expres-
sion and function in response to cisplatin. Further in
our Supplementary data, we also found EGFR with exon
19 deletion was also blocked in cytoplasm after cisplatin
treatment (Fig S1d). Therefore, we supposed that the
impaired EGFR nuclear localization was another reason
which contributed to ICL repair deﬁciency in NSCLC
harboring EGFR exon 19 deletion.
Furthermore, since ERCC1 endonuclease acted not only
in ICL repair but also played a role in completion of HR
following ICL repair,26 we considered that NSCLC cells
with EGFR exon 19 deletion might be HR deﬁcient and
sensitive to PARP inhibitor. Preclinical research observed
EGFR-mutant cell lines exhibited olaparib (PARP inhibi-
tor) sensitivity to a varying degree,22,27 thus identiﬁcation
of NSCLC patients who could beneﬁt from PARP inhibitor
treatment is an important issue. According to our results,
we supposed that EGFR exon 19 deletion might be a
potential biomarker for PARP inhibitor. However, this
hypothesis needs to be tested in NSCLC cell lines and clini-
cal trials in the future.
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Supporting Information
Additional Supporting Informationmay be found in the online
version of this article at the publisher’s website:
Figure S1 (a) Western blot analysis of ERCC1, phosphorylated
ERK, total ERK protein expression in HCC827 cells, before and
six hours after treatment with geﬁtinib. (b)Western blot analysis
of ERCC1, phosphorylated ERK, and total ERK protein
expression in NIH3T3 MEFs transfected EGFR L858R mutation
vectors, before and six hours after treatment with geﬁtinib.
ERCC1 values were expressed as ratio to those of corresponding
controls. (c)RT-PCR showing mRNA level of XPF expression in
NSCLC and human bronchial epithelial cell lines. (d)EGFR
cellular localization following 18 hours treatment of cisplatin in
EGFR wild-type and EGFR mutant NSCLC cell lines. All data
represent mean  SD based on two to three biology repeats.
Student’s t-test was used for statistical analysis between different
groups. * P < 0.05.
Thoracic Cancer (2020) © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd 9
L. Zhang et al. EGFR mutation regulated DDR through ERCC1 in NSCLC
